Top Abstracts with Expert Perspective: Lymphoproliferative Disorders (Lymphoma, CLL)
Tracks
-
| Sunday, April 27, 2025 |
| 4:20 PM - 5:50 PM |
| Lomond |
Speaker
Dr. David Lewis
Consultant Haematologist
Plymouth Hospitals NHS Trust
Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Untreated Older Mantle Cell Lymphoma Patients: The ENRICH trial
4:20 PM - 4:35 PM
Dr Euan Haynes
Registrar
Newcastle Upon Tyne University Hospitals
Real World Experience of Glofitamab and Epcoritamab: A Retrospective U.K. Multicentre Analysis
4:35 PM - 4:50 PM
Mx Gage Millen
Phd Candidate
University of Leicester
The Effects of Continuous Activation of T Cells on Bispecific Antibody (BsAb)-mediated Killing.
4:50 PM - 5:05 PM
Prof. John Radford
Professor of Medical Oncology
University of Manchester
Survival and Cause of Death After 16 Years of Follow-up in the UK RAPID Trial
5:05 PM - 5:20 PM
Dr Ruhi Kanani
Clinical Fellow
Natcan
Strengthening Non-Hodgkin Lymphoma Care through a new National Clinical Audit
5:20 PM - 5:35 PM
Dr Talha Munir
Consultant Haematologist
St James's Hospital NHS trust
Efficacy/Safety of the BTK Degrader NX-5948 in Chronic Lymphocytic Leukemia: An Ongoing Phase 1a/b Study
5:35 PM - 5:45 PM
Dr Talha Munir
Consultant Haematologist
St James's Hospital NHS trust
BGB-16673, a BTK Degrader, in Patients With R/R CLL/SLL: Preliminary Phase 1 Results from CaDAnCe-101
5:45 PM - 5:55 PMChair
Cathy Burton
Consultant Haematologist
Leeds Teaching Hospitals NHS Trust
